Altimmune, Inc. (NASDAQ:ALT) Receives $16.60 Consensus PT from Analysts

Altimmune, Inc. (NASDAQ:ALT) has earned an average recommendation of “Hold” from the nine analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $16.60.

ALT has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. B. Riley Financial cut their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a report on Friday, March 6th. Wall Street Zen lowered shares of Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday. William Blair restated a “market perform” rating on shares of Altimmune in a report on Thursday, March 5th. Finally, Citigroup restated a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th.

Insiders Place Their Bets

In related news, Director John Gill bought 12,500 shares of the company’s stock in a transaction on Tuesday, December 23rd. The stock was bought at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the acquisition, the director directly owned 12,500 shares in the company, valued at $51,250. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jerome Benedict Durso bought 20,000 shares of the business’s stock in a transaction on Friday, March 6th. The stock was bought at an average cost of $3.54 per share, with a total value of $70,800.00. Following the completion of the purchase, the chief executive officer directly owned 32,500 shares in the company, valued at approximately $115,050. The trade was a 160.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 55,527 shares of company stock worth $213,778 in the last three months. 4.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Altimmune

Hedge funds have recently modified their holdings of the company. Two Sigma Investments LP raised its stake in Altimmune by 356.6% during the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock worth $7,528,000 after purchasing an additional 1,559,562 shares during the period. State Street Corp boosted its holdings in Altimmune by 42.2% in the 4th quarter. State Street Corp now owns 5,119,703 shares of the company’s stock valued at $18,482,000 after purchasing an additional 1,518,448 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after buying an additional 1,206,514 shares during the period. Nuveen LLC grew its stake in shares of Altimmune by 514.9% in the 4th quarter. Nuveen LLC now owns 1,244,211 shares of the company’s stock valued at $4,492,000 after buying an additional 1,041,856 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Altimmune during the 4th quarter worth approximately $3,331,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Stock Down 0.5%

NASDAQ ALT opened at $3.86 on Friday. The business has a fifty day moving average price of $4.49 and a 200 day moving average price of $4.29. The company has a debt-to-equity ratio of 0.15, a quick ratio of 17.18 and a current ratio of 18.55. The company has a market cap of $502.07 million, a P/E ratio of -3.82 and a beta of 0.13. Altimmune has a one year low of $2.90 and a one year high of $7.73.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.00 million. Research analysts anticipate that Altimmune will post -1.35 EPS for the current fiscal year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.